Tibolone Improves Myocardial Perfusion in Postmenopausal Women With Ischemic Heart Disease
An Open-Label Exploratory Pilot Study
Roxana Campisi, MD*,1,*,
Jorge Camilletti, MD*,
Aníbal Mele, MD*,
Juan Erriest, MD*,
Pablo Pedroni, MD* and
Ariel Guiglioni, MD
* Instituto de Cardiología La Plata, Buenos Aires, Argentina.
Centro de Reproducción y Planificación Familiar, Buenos Aires, Argentina.
View larger version (17K):
[in a new window]
|
Figure 1 Baseline summed stress score (SSS) was moderate for both groups. In the treatment group, the six-month study exhibited a significant decline to a probably normal-average score, whereas it remained unchanged in control patients.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Average summed difference score (SDS) was moderate for both groups at baseline. It only was reduced in the treatment group. No changes were observed in the control group.
|
|
View larger version (99K):
[in a new window]
|
Figure 3 Example of single-photon emission computed tomography images in a patient receiving treatment with tibolone. (A) At baseline, the short axis, horizontal long axis, and vertical long axis show an extensive and severe reversible perfusion defect in the inferior and lateral walls. (B) Six months after tibolone therapy, there is a significant improvement in the perfusion defects during stress.
|
|
|
